The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib-Reference-Cited by-同舟云学术

The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib

Published:2013-01-30 Issue:1 Volume:161 Page:43-56
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Dasmahapatra Girija¹,Patel Hiral¹,Dent Paul,Fisher Richard I.²,Friedberg Jonathan²,Grant Steven

Affiliation:

1. Division of Hematology/Oncology; Department of Medicine; Virginia Commonwealth University; Richmond; VA; USA

2. Division of Hematology Oncology; University of Rochester Medical Center and the James P. Wilmot Cancer Center; Rochester; NY; USA

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.12206/fullpdf

Reference62 articles.

1. Proteasome inhibitors: a novel class of potent and effective antitumor agents;Adams;Cancer Research,1999

2. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts;An;Cell Death and Differentiation,1998

3. The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Inhibits Growth of ABC DLBCL Tumors In Vivo and in Vitro by Preventing Activation of Pro-Survival NF-{kappa}B pathways;Balbasubramanian;Blood (ASH annual Meeting Abstracts),2011

4. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction;Bea;Blood,2005

5. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets;Bedford;Nature reviews. Drug discovery,2011

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interplay between proteasome inhibitors and NF-κB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors;Cell Communication and Signaling;2024-02-08

2. Expression of “DNA damage response” pathway genes in diffuse large B‐cell lymphoma: The potential for exploiting synthetic lethality;Hematological Oncology;2023-10-05

3. Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13);eClinicalMedicine;2023-10

4. Ibrutinib combined with low‐dose histone deacetylases inhibitor chidamide synergistically enhances the anti‐tumor effect in B‐cell lymphoma;Hematological Oncology;2022-08-24

5. DLBCL 1L—What to Expect beyond R-CHOP?;Cancers;2022-03-11